Cibc Asset Management Inc Ultragenyx Pharmaceutical Inc. Transaction History

Cibc Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$45.8 - $85.4 $133,186 - $248,343	-2,908 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$73.71 - $87.86 $12,088 - $14,409	164 Added 5.98%	2,908 $245,000
Q3 2021 Nov 09, 2021	BUY	$77.92 - $102.4 $22,986 - $30,208	295 Added 12.05%	2,744 $247,000
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $20,845 - $32,707	195 Added 8.65%	2,449 $279,000
Q4 2020 Feb 03, 2021	BUY	$84.4 - $177.39 $190,237 - $399,837	2,254 New	2,254 $312,000

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.